Research | Departments
Research
Departments
Research highlights of Laboratory of Thoracic Precision Oncology
Dr. Chou’ research topics include lung pathology, molecular pathology of lung cancer, and precision medicine of cancer. As a practicing pulmonary pathologist, the projects Dr. Chou has been working on in recent 20 years focus on the molecular mechanisms of tumor metastasis and prediction and prognostication biomarkers of lung cancer. Through grants sponsored by the government as well as the industries, Dr. Chou has accomplished several seminal scientific discoveries, which are well illustrated in his more than 150 articles published in international SCI journals. With the continuous efforts on the study of lung cancer, Dr. Chou’s laboratory is to apply state-of-the-art molecular pathology and precision medicine technologies on human specimens to search for biomarkers and therapy targets of tumor occurrence, progression, recurrence and drug resistance in lung cancer.
Email | tehying@tmu.edu.tw
Profile | Academic Hub/Pure Experts
Teh-Ying Chou
Teh-Ying Chou
Graduate Institute of Clinical Medicine
Professor (M.D., Ph.D.)
Research Interests
Pulmonary Pathology, Molecular Pathology of Lung Cancer Metastasis, Invasion and Metastasis of Lung Cancer, Cancer Glycobiology, Precision Medicine
Laboratory
Laboratory of Thoracic Precision Oncology
Prof./Dr. Chou was born in 1959 and received an M.D. degree from the National Yang-Ming Medical College, Taipei, Taiwan in 1984. After the anatomical pathology residency training at the Taipei Veterans General Hospital, he went to the Johns Hopkins University School of Medicine and received a Ph.D. degree in Biochemistry in 1995.
1999 – 2002
In his thesis work advised by Professor Gerald Hart and Professor Chi Dang, Dr. Chou provided the evidence of O-GlcNAc glycosylation of the oncoprotein c-Myc. From 1999 to 2001, he completed an anatomic pathology residency at the Washington University Medical Center/Barnes-Jewish Hospital and, from 2001 to 2002, a Calendar Binford Clinical Fellowship in Pulmonary Pathology with Professor William D. Travis in the Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology.
2002 – 2017
After returning to his hometown in 2002, Dr. Chou resumed an attending pathologist position at the Taipei Veterans General Hospital. From 2014 to 2017, Dr. Chou was President of the Taiwan Society of Pathology as well as the Taiwan Division of International Academy of Pathology. Since 2014, Dr. Chou has been a member of the Pathology Committee of International Association for the Study of Lung Cancer (IASLC).
In 2016, Dr. Chou received a master degree in Business Administration from the National Taiwan University, Taipei, Taiwan. Dr. Chou is currently Professor of the Graduate Institute of Clinical Medicine, Taipei Medical University and Vice Superintendent for Research and Development, Taipei Medical University Hospital.
His major scientific achievements include the identification of a regulatory hub of developmental/stemness signaling and invadopodia that drives cancer stemness and progression, which may hold promises for development into novel CSC-targeted therapies. He co-identified a cell-intrinsic and chromatin-mediated cellular “death checkpoint” whereby most malignant tumors resist cytotoxic stress; the targeting of which yields an exciting opportunity for sensitizing malignant tumors to chemotherapy and immunotherapy.
01
Jou-Chun Chou
Ph.D. (Postdoctoral Fellow)
02
Chi-Lu Chiang
MD (PhD Student)
03
Yu-Jen Chiu
MD (PhD Student)
04
Jie-Hsi Wu
MS (PhD Student)
05
Lu-Ping Leu
MS (PhD Student)
06
Nen-Hsiang Tsen
MD (Research Assistant)
2023
Yang CY, Yeh YC, Wang LC, Lin YY, Lin SY, Wang SY, Chu PY, Liu ZY, Su YC, Ho HL*, Chou TY*.
Genomic profiling with large-scale next-generation sequencing panels distinguishes separate primary lung adenocarcinomas from intrapulmonary metastases.
Modern Pathology. 36 (2023) 100047
Abstract
–
2022
Lin YY, Wang LC, Hsieh YH, Hung YL, Chen YA, Lin YC, Lin YY, Chou TY*.
Computer-assisted threedimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology.
Journal of Translational Medicine. (2022) Mar 16;20(1):131
Abstract
–
Lin CH, Liao CC, Wang SY, Peng CY, Yeh YC, Chen MY*, Chou TY*. Comparative O-GlcNAc Proteomic
Analysis Reveals a Role of O-GlcNAcylated SAM68 in Lung Cancer Aggressiveness.
Cancers (Basel). (2022) Jan 4;14(1):243
Abstract
–
2021
Lin YY, Wang YC, Yeh DW, Hung CY, Yeh YC, Ho HL, Mon HC, Chen MY, Wu YC, Chou TY*.
Gene Expression Profile in Primary Tumor Is Associated with Brain-Tropism of Metastasis from Lung Adenocarcinoma.
International Journal of Molecular Science. (2021) Dec 13;22(24):13374
Abstract
–
Lin CH, Liao CC, Chen MY, Chou TY*.
Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
International Journal of Molecular Science. (2021) Mar 27;22(7):3463
Abstract
–
Contact Us
Total Users : 239173
